Atom | Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Funding Amounts: Up to $500,000 in direct costs per year, for a maximum project period of 5 years.

Summary: Supports research to define the impact of defective HIV proviruses on HIV persistence, pathogenesis, and cure strategies during antiretroviral treatment; clinical trials are not allowed.

Key Information: Human samples are required; SIV/SHIV models and clinical trials are not permitted; foreign organizations are eligible.

Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)

Sign in to see full grant listing